文献速递真菌感染艾滋病与性传播感染

HIV相关隐球菌脑膜炎全球疾病负担:更新分析

Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis.
PubMed 文献 · Lancet Infect Dis · 2017-05-05

该研究基于2014年联合国艾滋病规划署成人HIV及抗逆转录病毒治疗覆盖数据,结合中低收入国家队列的CD4<100细胞/μL、病毒学失败和失访估计,以及全球46项研究的隐球菌抗原血症患病率,估算2014年全球HIV相关隐球菌脑膜炎发病率与死亡数。

要点

  • 2014年全球HIV相关隐球菌脑膜炎估计223 100例,死亡181 100例。
  • 撒哈拉以南非洲占73%病例(162 500例)和75%死亡(135 900例)。

核心结论

  • HIV相关隐球菌病负担仍巨大,主要集中在撒哈拉以南非洲。
  • 隐球菌脑膜炎是HIV治疗项目失败的指标,及时HIV检测和快速链接护理仍是紧迫优先事项。

研究设计与样本

  • 基于2014年联合国艾滋病规划署成人(>15岁)HIV及抗逆转录病毒治疗覆盖估计。
  • CD4<100细胞/μL、病毒学失败发生率和失访数据来自中低收入国家已发表多国队列。
  • 隐球菌抗原血症患病率按国家来自全球46项研究。
  • 计算高危人群:CD4<100细胞/μL未治疗者,及CD4<100细胞/μL治疗但失访或病毒学失败者。

主要发现

  • 全球278 000人(95%CI 195 500-340 600)隐球菌抗原阳性。
  • 2014年全球隐球菌脑膜炎新发病例223 100例(95%CI 150 600-282 400)。
  • 撒哈拉以南非洲162 500例(95%CI 113 600-193 900),占73%。
  • 全球死亡181 100例(95%CI 119 400-234 300),撒哈拉以南非洲135 900例(75%;95%CI 93 900-163 900)。

临床怎么用

  • 应重视CD4<100细胞/μL的HIV感染者隐球菌感染风险。
  • 加强及时HIV检测和快速链接护理以降低隐球菌脑膜炎负担。
  • 隐球菌脑膜炎可作为监测HIV治疗项目失败的指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cryptococcus is the most common cause of meningitis in adults living with HIV in sub-Saharan Africa. Global burden estimates are crucial to guide prevention strategies and to determine treatment needs, and we aimed to provide an updated estimate of global incidence of HIV-associated cryptococcal disease. METHODS: We used 2014 Joint UN Programme on HIV and AIDS estimates of adults (aged >15 years) with HIV and antiretroviral therapy (ART) coverage. Estimates of CD4 less than 100 cells per μL, virological failure incidence, and loss to follow-up were from published multinational cohorts in low-income and middle-income countries. We calculated those at risk for cryptococcal infection, specifically those with CD4 less than 100 cells/μL not on ART, and those with CD4 less than 100 cells per μL on ART but lost to follow-up or with virological failure. Cryptococcal antigenaemia prevalence by country was derived from 46 studies globally. Based on cryptococcal antigenaemia prevalence in each country and region, we estimated the annual numbers of people who are developing and dying from cryptococcal meningitis. FINDINGS: We estimated an average global cryptococcal antigenaemia prevalence of 6·0% (95% CI 5·8-6·2) among people with a CD4 cell count of less than 100 cells per μL, with 278 000 (95% CI 195 500-340 600) people positive for cryptococcal antigen globally and 223 100 (95% CI 150 600-282 400) incident cases of cryptococcal meningitis globally in 2014. Sub-Saharan Africa accounted for 73% of the estimated cryptococcal meningitis cases in 2014 (162 500 cases [95% CI 113 600-193 900]). Annual global deaths from cryptococcal meningitis were estimated at 181 100 (95% CI 119 400-234 300), with 135 900 (75%; [95% CI 93 900-163 900]) deaths in sub-Saharan Africa. Globally, cryptococcal meningitis was responsible for 15% of AIDS-related deaths (95% CI 10-19). INTERPRETATION: Our analysis highlights the substantial ongoing burden of HIV-associated cryptococcal disease, primarily in sub-Saharan Africa. Cryptococcal meningitis is a metric of HIV treatment programme failure; timely HIV testing and rapid linkage to care remain an urgent priority. FUNDING: None.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Rajasingham R, Smith RM, Park BJ, et al. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. Lancet Infect Dis. 2017. PMID: 28483415. doi:10.1016/S1473-3099(17)30243-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。